Stock Chart
JAZZ
Type: SELL growth_1yr
Strike: $280
Premium: $27.50
Expiry: Jun 17, 2027
Target: $269
Score: -100
LEAPs are long-term options (1+ year) with less time decay.
Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech
Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity
Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Technical Chart
About JAZZ - Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Key Statistics
More JAZZ Analysis
This JAZZ stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track JAZZ's price movements with trendlines, gamma walls, and key support/resistance levels.